Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis

Future Microbiology

Volumn 8, Issue 3, 2013, Pages 323-352

  Saha, Abhik ^a   Robertson, Erle S ^b  

^a PRESIDENCY UNIVERSITY   (India)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

apoptosis; cell cycle; cyclins; E2F1; EBNA 3C; EBV; p53; ubiquitin proteasome pathway

Indexed keywords

BIM PROTEIN; CYCLIN A; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DEAD BOX PROTEIN 20; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3C; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE BINDING PROTEIN; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; VIRUS DNA;

ADAPTIVE IMMUNITY; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE ASSOCIATION; DNA BINDING; DNA REPAIR; DNA REPLICATION; EPIGENETIC REPRESSION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EXON; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HYDROPHILICITY; IMMUNOBLOTTING; IMMUNOCOMPROMISED PATIENT; LATENT VIRUS INFECTION; NONHUMAN; OPEN READING FRAME; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RNA STABILITY; TRANSLATION INITIATION; VIRUS GENE; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS STRAIN;

ANTIGENS, VIRAL; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; VIRUS LATENCY;

EID: 84874716795     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.147     Document Type: Review

References (158)

1. Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin. Cancer Res. 17(10), 3056-3063 (2011).
2. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356(1408), 461-473 (2001).
3. Vereide D, Sugden B. Insights into the evolution of lymphomas induced by Epstein-Barr virus. Adv. Cancer Res. 108, 1-19 (2010).
4. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin. Cancer Res. 10(3), 803-821 (2004).
5. Saha A, Kaul R, Murakami M, Robertson ES. Tumor viruses and cancer biology: modulating signaling pathways for therapeutic intervention. Cancer Biol. Ther. 10(10), 961-978 (2010).
6. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4(10), 757-768 (2004).
7. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol. 1, 375-404 (2006).
8. G, Klein E, Kashuba E. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem. Biophys. Res. Commun. 396(1), 67-73 (2010).
9. Dolcetti R GM, Gloghini A, Carbone A. EBV-associated tumors: pathogenetic insights for improved disease monitoring and treatment. Curr. Cancer Ther. Rev. 1(1), 27-44 (2005).
10. Rezk SA WL. Epstein-Barr virus-associated lymphoproliferative disorders. Hum. Pathol. 38(9), 1293-1304 (2007).
11. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun. Rev. 7(2), 96-101 (2007).
12. Ma SD, Hegde S, Young KH et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J. Virol. 85(1), 165-177 (2010).
13. Li R, Hayward SD. The Ying-Yang of the virus-host interaction: control of the DNA damage response. Future Microbiol. 6(4), 379-383 (2011).
14. Hertle ML, Popp C, Petermann S et al. Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog. 5(7), e1000506 (2009).
15. Subramanian C, Knight JS, Robertson ES. The Epstein Barr nuclear antigen EBNA3C regulates transcription, cell transformation and cell migration. Front. Biosci. 7, d704-d716 (2002).
16. West MJ. Structure and function of the Epstein-Barr virus transcription factor, EBNA 3C. Curr. Protein Pept. Sci. 7(2), 123-136 (2006).
17. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ. Epigenetic repression of p16INK4A by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog. 6(6), e1000951 (2010).
18. Yenamandra SP, Sompallae R, Klein G, Kashuba E. Comparative analysis of the Epstein-Barr virus encoded nuclear proteins of EBNA-3 family. Comput. Biol. Med. 39(11), 1036-1042 (2009).
19. Zhao B, Dalbies-Tran R, Jiang H et al. Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses. J. Virol. 77(10), 5639-5648 (2003).
20. Krauer K, Buck M, Flanagan J, Belzer D, Sculley T. Identification of the nuclear localization signals within the Epstein-Barr virus EBNA-6 protein. J. Gen. Virol. 85(Pt 1), 165-172 (2004).
21. Buck M, Burgess A, Stirzaker R, Krauer K, Sculley T. Epstein-Barr virus nuclear antigen 3A contains six nuclear-localization signals. J. Gen. Virol. 87(Pt 10), 2879-2884 (2006).
22. Burgess A, Buck M, Krauer K, Sculley T. Nuclear localization of the Epstein-Barr virus EBNA3B protein. J. Gen. Virol. 87(Pt 4), 789-793 (2006).
23. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog. 5(6), e1000492 (2009).
24. White RE, Groves IJ, Turro E, Yee J, Kremmer E, Allday MJ. Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5(11), e13979 (2010).
25. White RE, Ramer PC, Naresh KN et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Invest. 122(4), 1487-1502 (2012).
26. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc. Natl Acad. Sci. USA 108(5), 1919-1924 (2011).
27. Maruo S, Wu Y, Ito T, Kanda T, Kieff ED, Takada K. Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth. Proc. Natl Acad. Sci. USA 106(11), 4419-4424 (2009).
28. Kempkes B, Pich D, Zeidler R, Sugden B, Hammerschmidt W. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J. Virol. 69(1), 231-238 (1995).
29. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67(4), 2014-2025 (1993).
30. Petti L, Sample J, Wang F, Kieff E. A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J. Virol. 62(4), 1330-1338 (1988).
31. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. Epstein-Barr virus nuclear antigen 3C augments MDM2-mediated p53 ubiquitination and degradation by deubiquitinating MDM2. J. Virol. 83(9), 4652-4669 (2009).
32. Krauer KG, Buck M, Belzer DK, Flanagan J, Chojnowski GM, Sculley TB. The Epstein-Barr virus nuclear antigen-6 protein colocalizes with EBNA-3 and survival of motor neurons protein. Virology 318(1), 280-294 (2004).
33. Yan X, Mouillet JF, Ou Q, Sadovsky Y. A novel domain within the DEAD-box protein DP103 is essential for transcriptional repression and helicase activity. Mol. Cell Biol. 23(1), 414-423 (2003).
34. Allday MJ, Farrell PJ. Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J. Virol. 68(6), 3491-3498 (1994).
35. Zhao B, Mar JC, Maruo S et al. Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc. Natl Acad. Sci. USA 108(1), 337-342 (2010).
36. Radkov SA, Bain M, Farrell PJ, West M, Rowe M, Allday MJ. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J. Virol. 71(11), 8552-8562 (1997).
37. Lin J, Johannsen E, Robertson E, Kieff E. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J. Virol. 76(1), 232-242 (2002).
38. McClellan MJ, Khasnis S, Wood CD et al. Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and -distal binding elements. J. Virol. 86(9), 5165-5178 (2012).
39. Zhao B, Sample CE. Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/spi-B binding site. J. Virol. 74(11), 5151-5160 (2000).
40. Subramanian C, Hasan S, Rowe M, Hottiger M, Orre R, Robertson ES. Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. J. Virol. 76(10), 4699-4708 (2002).
41. Radkov SA, Touitou R, Brehm A et al. Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J. Virol. 73(7), 5688-5697 (1999).
42. Knight JS, Lan K, Subramanian C, Robertson ES. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J. Virol. 77(7), 4261-4272 (2003).
43. Bain M, Watson RJ, Farrell PJ, Allday MJ. Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J. Virol. 70(4), 2481-2489 (1996).
44. Fuentes-Panana EM, Peng R, Brewer G, Tan J, Ling PD. Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway. J. Virol. 74(17), 8166-8175 (2000).
45. Zimber-Strobl U, Strobl LJ. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin. Cancer Biol. 11(6), 423-434 (2001).
46. Zhou S, Fujimuro M, Hsieh JJ, Chen L, Hayward SD. A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J. Virol. 74(4), 1939-1947 (2000).
47. Lee S, Sakakibara S, Maruo S et al. Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J. Virol. 83(23), 12368-12377 (2009).
48. Kashuba E, Kashuba V, Sandalova T, Klein G, Szekely L. Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyltransferase. BMC Cell Biol. 3, 23 (2002).
49. Tanigaki K, Honjo T. Two opposing roles of RBP-J in Notch signaling. Curr. Top. Dev. Biol. 92, 231-252 (2010).
50. Robertson ES, Lin J, Kieff E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J. Virol. 70(5), 3068-3074 (1996).
51. Rando OJ. Combinatorial complexity in chromatin structure and function: revisiting the histone code. Curr. Opin. Genet. Dev. 22(2), 148-155 (2012).
52. Bartova E, Krejci J, Harnicarova A, Galiova G, Kozubek S. Histone modifications and nuclear architecture: a review. J. Histochem. Cytochem. 56(8), 711-721 (2008).
53. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76, 75-100 (2007).
54. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ. Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J. Virol. 75(16), 7749-7755 (2001).
55. Zhao LJ, Subramanian T, Vijayalingam S, Chinnadurai G. PLDLS-dependent interaction of E1A with CtBP: regulation of CtBP nuclear localization and transcriptional functions. Oncogene 26(54), 7544-7551 (2007).
56. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ. Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J. Biol. Chem. 277(49), 47197-47204 (2002).
57. Steeg PS, Bevilacqua G, Kopper L et al. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl Cancer Inst. 80(3), 200-204 (1988).
58. Saha A, Robertson ES. Functional modulation of the metastatic suppressor Nm23-H1 by oncogenic viruses. FEBS Lett. 585(20), 3174-3184 (2011).
59. Murakami M, Kaul R, Kumar P, Robertson ES. Nucleoside diphosphate kinase/Nm23 and Epstein-Barr virus. Mol. Cell Biochem. 329(1-2), 131-139 (2009).
60. Choudhuri T, Murakami M, Kaul R et al. Nm23-H1 can induce cell cycle arrest and apoptosis in B cells. Cancer Biol. Ther. 9(12), 1065-1078 (2010).
61. Kaul R, Murakami M, Choudhuri T, Robertson ES. Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. J. Virol. 81(19), 10352-10361 (2007).
62. Subramanian C, Cotter MA 2nd, Robertson ES. Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat. Med. 7(3), 350-355 (2001).
63. Kelly GL, Milner AE, Tierney RJ et al. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J. Virol. 79(16), 10709-10717 (2005).
64. Kaul R, Murakami M, Lan K, Choudhuri T, Robertson ES. EBNA3C can modulate the activities of the transcription factor Necdin in association with metastasis suppressor protein Nm23-H1. J. Virol. 83(10), 4871-4883 (2009).
65. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J. Neurosci. Res. 67(6), 705-712 (2002).
66. Matsumoto K, Taniura H, Uetsuki T, Yoshikawa K. Necdin acts as a transcriptional repressor that interacts with multiple guanosine clusters. Gene 272(1-2), 173-179 (2001).
67. Harper JV, Brooks G. The mammalian cell cycle: an overview. Methods Mol. Biol. 296, 113-153 (2005).
68. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9(3), 153-166 (2009).
69. Malumbres M, Harlow E, Hunt T et al. Cyclin-dependent kinases: a family portrait. Nat. Cell Biol. 11(11), 1275-1276 (2009).
70. Hochegger H, Takeda S, Hunt T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat. Rev. Mol. Cell Biol. 9(11), 910-916 (2008).
71. Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol. Ther. 13(7), 451-457 (2012).
72. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35(4), 495-516 (2007).
73. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5(11), 876-885 (2005).
74. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. CDK inhibitors: from the bench to clinical trials. Curr. Drug Targets 11(3), 279-290 (2010).
75. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 24(17), 2796-2809 (2005).
76. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9(11), 785-797 (2009).
77. Poznic M. Retinoblastoma protein: a central processing unit. J. Biosci. 34(2), 305-312 (2009).
78. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36(3), 131-149 (2003).
79. Flatt PM, Pietenpol JA. Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Drug Metab. Rev. 32(3-4), 283-305 (2000).
80. Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J. Biomed. Biotechnol. 2012, 170325 (2012).
81. Yang J, Xu ZP, Huang Y, Hamrick HE, Duerksen-Hughes PJ, Yu YN. ATM and ATR: sensing DNA damage. World J. Gastroenterol. 10(2), 155-160 (2004).
82. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6(9), 1006-1010 (2007).
83. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73-112 (2010).
84. Yao Y, Dai W. Mitotic checkpoint control and chromatin remodeling. Front. Biosci. 17, 976-983 (2012).
85. Sun SC, Kim NH. Spindle assembly checkpoint and its regulators in meiosis. Hum. Reprod. Update 18(1), 60-72 (2012).
86. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, Allday MJ. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13(12), 2541-2549 (1996).
87. Knight JS, Sharma N, Robertson ES. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc. Natl Acad. Sci. USA 102(51), 18562-18566 (2005).
88. Kashuba E, Yurchenko M, Yenamandra SP et al. EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc. Natl Acad. Sci. USA 105(14), 5489-5494 (2008).
89. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, Takada K. Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc. Natl Acad. Sci. USA 103(51), 19500-19505 (2006).
90. Saha A, Halder S, Upadhyay SK et al. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog. 7(2), e1001275 (2011).
91. Bashir T, Pagano M. Don't skip the G1 phase: how APC/CCdh1 keeps SCFSKP2 in check. Cell Cycle 3(7), 850-852 (2004).
92. Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, Robertson ES. Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J. Virol. 82(8), 4082-4090 (2008).
93. Knight JS, Sharma N, Robertson ES. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol. Cell Biol. 25(5), 1749-1763 (2005).
94. von der Lehr N, Johansson S, Larsson LG. Implication of the ubiquitin/proteasome system in Myc-regulated transcription. Cell Cycle 2(5), 403-407 (2003).
95. JS, Sharma N, Kalman DE, Robertson ES. A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J. Virol. 78(23), 12857-12867 (2004).
96. Knight JS, Robertson ES. Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J. Virol. 78(4), 1981-1991 (2004).
97. Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, Robertson ES. E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog. 8(3), e1002573 (2012).
98. Yi F, Saha A, Murakami M et al. Epstein- Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388(2), 236-247 (2009).
99. Saha A, Bamidele A, Murakami M, Robertson ES. EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J. Virol. 85(5), 2079-2088 (2011).
100. Spender LC, Cannell EJ, Hollyoake M et al. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J. Virol. 73(6), 4678-4688 (1999).
101. Palmero I, Holder A, Sinclair AJ, Dickson C, Peters G. Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene 8(4), 1049-1054 (1993).
102. Kim HR, Jeong JA, Park CH, Lee SK, Lee WK, Jang YS. A role for cell cycle proteins in the serum-starvation resistance of Epstein- Barr virus immortalized B lymphocytes. Biochem. Cell Biol. 80(4), 407-413 (2002).
103. Murai Y, Dobashi Y, Okada E et al. Study on the role of G1 cyclins in Epstein-Barr virus-associated human lymphomas maintained in severe combined immune deficiency (SCID) mice. Int. J. Cancer 92(2), 232-239 (2001).
104. Velasco-Velazquez MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG. Examining the role of cyclin D1 in breast cancer. Future Oncol. 7(6), 753-765 (2011).
105. Lin DI, Barbash O, Kumar KG et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol. Cell 24(3), 355-366 (2006).
106. Pontano LL, Diehl JA. Speeding through cell cycle roadblocks: Nuclear cyclin D1- dependent kinase and neoplastic transformation. Cell Div. 3, 12 (2008).
107. Parker GA, Touitou R, Allday MJ. Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19(5), 700-709 (2000).
108. Nikitin PA, Yan CM, Forte E et al. An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 8(6), 510-522 (2010).
109. Vardy L, Pesin JA, Orr-Weaver TL. Regulation of Cyclin A protein in meiosis and early embryogenesis. Proc. Natl Acad. Sci. USA 106(6), 1838-1843 (2009).
110. Mateo F, Vidal-Laliena M, Pujol MJ, Bachs O. Acetylation of cyclin A: a new cell cycle regulatory mechanism. Biochem. Soc. Trans. 38(Pt 1), 83-86 (2010).
111. Jessus C, Ozon R. How does Xenopus oocyte acquire its competence to undergo meiotic maturation? Biol. Cell 96(3), 187-192 (2004).
112. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 11(3), 961-971 (1992).
113. Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES. The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J. Virol. 81(12), 6718-6730 (2007).
114. Wade M, Allday MJ. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol. Cell Biol. 20(4), 1344-1360 (2000).
115. Benedict CA, Norris PS, Ware CF. To kill or be killed: viral evasion of apoptosis. Nat. Immunol. 3(11), 1013-1018 (2002).
116. White E. Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ. 13(8), 1371-1377 (2006).
117. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. Cancer Res. 30, 87 (2011).
118. Essmann F, Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br. J. Pharmacol. 165(2), 328-344 (2012).
119. Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 28(3), 128-136 (2012).
120. Tan S, de Vries EG, van der Zee AG, de Jong S. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr. Cancer Drug Targets 12(2), 170-184 (2012).
121. Cai Q, Verma SC, Lu J, Robertson ES. Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv. Virus Res. 78, 87-142 (2010).
122. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557-582 (2008).
123. Taira N, Yoshida K. Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol. Histopathol. 27(4), 437-443 (2012).
124. Gu B, Zhu WG. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 8(5), 672-684 (2012).
125. Pei D, Zhang Y, Zheng J. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 3(3), 228-235 (2012).
126. Di J, Zhang Y, Zheng J. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. Curr. Cancer Drug Targets 11(8), 987-994 (2011).
127. Russell M, Berardi P, Gong W, Riabowol K. Grow-ING, age-ING and die-ING: ING proteins link cancer, senescence and apoptosis. Exp. Cell Res. 312(7), 951-961 (2006).
128. Jafarnejad SM, Li G. Regulation of p53 by ING family members in suppression of tumor initiation and progression. Cancer Metastasis Rev. 31(1-2), 55-73 (2011).
129. Soliman MA, Riabowol K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem. Sci. 32(11), 509-519 (2007).
130. Dalla Via L, Nardon C, Fregona D. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Med. Chem. 4(4), 525-543 (2012).
131. Forte E, Luftig MA. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J. Virol. 83(6), 2491-2499 (2009).
132. Shen H, Maki CG. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr. Pharm. Des. 17(6), 560-568 (2011).
133. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol. Cell Biol. 23(14), 4939-4947 (2003).
134. Grundhoff AT, Kremmer E, Tureci O et al. Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C. J. Biol. Chem. 274(27), 19136-19144 (1999).
135. Fuller-Pace FV, Jacobs AM, Nicol SM. Modulation of transcriptional activity of the DEAD-box family of RNA helicases, p68 (Ddx5) and DP103 (Ddx20), by SUMO modification. Biochem. Soc. Trans. 35(Pt 6), 1427-1429 (2007).
136. Zhou J, Zheng X, Shen H. Targeting RNA-splicing for SMA treatment. Mol. Cells 33(3), 223-228 (2012).
137. Cai Q, Guo Y, Xiao B et al. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog. 7(12), e1002418 (2011).
138. Wu Z, Zheng S, Yu Q. The E2F family and the role of E2F1 in apoptosis. Int. J. Biochem. Cell Biol. 41(12), 2389-2397 (2009).
139. Polager S, Ginsberg D. p53 and E2F: partners in life and death. Nat. Rev. Cancer 9(10), 738-748 (2009).
140. Wu Z, Yu Q. E2F1-mediated apoptosis as a target of cancer therapy. Curr. Mol. Pharmacol. 2(2), 149-160 (2009).
141. Molina-Privado I, Rodriguez-Martinez M, Rebollo P et al. E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Res. 69(9), 4052-4058 (2009).
142. Pediconi N, Ianari A, Costanzo A et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat. Cell Biol. 5(6), 552-558 (2003).
143. Jendrossek V. The intrinsic apoptosis pathways as a target in anticancer therapy. Curr. Pharm. Biotechnol. 13(8), 1426-1438 (2012).
144. Hughes P, Bouillet P, Strasser A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr. Dir. Autoimmun. 9, 74-94 (2006).
145. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl Acad. Sci. USA 101(16), 6164-6169 (2004).
146. Richter-Larrea JA, Robles EF, Fresquet V et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116(14), 2531-2542 (2010).
147. Molyneux EM, Rochford R, Griffin B et al. Burkitt's lymphoma. Lancet 379(9822), 1234-1244 (2012).
148. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27(4), 421-433 (2008).
149. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22(1), 50-55 (2012).
150. Ocker M, Hopfner M. Apoptosis-modulating drugs for improved cancer therapy. Eur. Surg. Res. 48(3), 111-120 (2012).
151. Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int. J. Cancer 124(8), 1745-1755 (2009).
152. Schlee M, Schuhmacher M, Holzel M, Laux G, Bornkamm GW. c-Myc impairs immunogenicity of human B cells. Adv. Cancer Res 97, 167-188 (2007).
153. Graham JP, Arcipowski KM, Bishop GA. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol. Rev. 237(1), 226-248 (2010).
154. Johannsen E, Miller CL, Grossman SR, Kieff E. EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J. Virol. 70(6), 4179-4183 (1996).
155. Garrido JL, Maruo S, Takada K, Rosendorff A. EBNA3C interacts with Gadd34 and counteracts the unfolded protein response. Virol. J. 6, 231 (2009).
156. Cotter MA 2nd, Robertson ES. Modulation of histone acetyltransferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha. Mol. Cell Biol. 20(15), 5722-5735 (2000).
157. Subramanian C, Robertson ES. The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription. J. Virol. 76(17), 8702-8709 (2002).
158. Rosendorff A, Illanes D, David G, Lin J, Kieff E, Johannsen E. EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J. Virol. 78(1), 367-377 (2004).